Legacy Trust reduced its stake in Stryker Corporation (NYSE:SYK – Free Report) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,162 shares of the medical technology company’s stock after selling 2,005 shares during the quarter. Stryker accounts for 1.4% of Legacy Trust’s portfolio, making the stock its 24th largest position. Legacy Trust’s holdings in Stryker were worth $8,219,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. boosted its position in shares of Stryker by 16.3% during the third quarter. Eurizon Capital SGR S.p.A. now owns 107,386 shares of the medical technology company’s stock worth $29,587,000 after buying an additional 15,048 shares during the period. Nikulski Financial Inc. grew its holdings in shares of Stryker by 6.1% during the third quarter. Nikulski Financial Inc. now owns 8,762 shares of the medical technology company’s stock worth $2,413,000 after buying an additional 502 shares in the last quarter. R Squared Ltd acquired a new stake in Stryker in the 3rd quarter valued at approximately $351,000. Maryland State Retirement & Pension System raised its position in Stryker by 15.3% in the 3rd quarter. Maryland State Retirement & Pension System now owns 21,396 shares of the medical technology company’s stock valued at $5,892,000 after buying an additional 2,835 shares during the last quarter. Finally, NBH Bank raised its position in Stryker by 2.8% in the 3rd quarter. NBH Bank now owns 1,516 shares of the medical technology company’s stock valued at $417,000 after buying an additional 42 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 901,267 shares of company stock valued at $297,123,701. 4.60% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on SYK. Johnson Rice downgraded Stryker to a “hold” rating in a research report on Friday, October 30th. Deutsche Bank decreased their price target on shares of Stryker from $315.00 to $275.00 and set a “hold” rating for the company in a research note on Friday, October 30th. BTIG Research lowered their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Robert W. Baird cut their price objective on shares of Stryker from $385.00 to $334.00 in a research report on Friday, October 30th. Finally, Canaccord Genuity Group cut shares of Stryker from a “buy” rating to a “hold” rating and reduced their target price for the stock from $385.00 to $300.00 in a report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $342.19.
Get Our Latest Stock Analysis on Stryker
Stryker Stock Down 2.1%
SYK stock opened at $312.17 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average price of $292.28 and a two-hundred day moving average price of $322.83. The company has a market cap of $118.84 billion, a price-to-earnings ratio of 33.24, a P/E/G ratio of 2.19 and a beta of 0.78. Stryker Corporation has a twelve month low of $267.00 and a twelve month high of $389.33.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.19 EPS. Analysts anticipate that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Featured Articles
- Five stocks we like better than Stryker
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
